New Delhi, Sep 6 (IANS) A team of researchers has made a major breakthrough in predicting the severity of triple-negative breast cancer (TNBC).
Researchers at the National Utah Huntsman Cancer Institute in the Mountain West in the US have gained new insights into the prognosis of triple-negative breast cancer (TNBC).
There is no reliable way to predict the recurrence of a rare type of breast cancer (TNBC) following treatments such as chemotherapy and surgery.
The study, published in the journal JCO Precision Oncology, describes a new system that can accurately predict TNBC.
The researchers developed a patient-derived xenograft (PDX) model to assess the growth of an individual tumor and then implanted it into mice to assess the aggressiveness of TNBC.
This system is more accurate than existing methods in predicting recurrence. This makes it possible to quickly and accurately assess the aggressiveness of cancer.
This research could directly impact patient care and lead to more personalized treatment plans for patients with recurrent TNBC.
Cindy Matson, MD, co-author of the study and chief of the Breast and Gynecology Center at Huntsman Cancer Institute, said the study has the potential to help create more customized treatment plans for individuals with recurrent triple-negative breast cancer.
Practical benefits include testing specific drugs on PDX models and providing valuable insights for clinicians in treatment decisions.
“The results of the study are important, as tumor growth in PDX models often indicates highly aggressive cancer, making it difficult to treat in most cases,” the authors said.
–IANS
AKS/CBT
